Matrilysin in early stage intestinal tumorigenesis

APMIS

Volumn 107, Issue 1, 1999, Pages 102-110

  Fingleton, Barbara M ^a   Heppner Goss, Kathleen J ^a,b   Crawford, Howard C ^a   Matrisian, Lynn M ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Animal models; APC; catenin; Colon cancer; Matrilysin; Min

Indexed keywords

MATRILYSIN;

CANCER INVASION; COLON CARCINOGENESIS; COLON CARCINOMA; ENZYME ACTIVITY; ENZYME REGULATION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; METASTASIS INHIBITION; METASTASIS POTENTIAL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN TARGETING; REVIEW; TREATMENT PLANNING;

EID: 0033047119     PISSN: 09034641     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1699-0463.1999.tb01532.x     Document Type: Review

References (50)

1. 1. Woessner JF Jr. The matrix metalloproteinase family. In: Parks WC, Mecham RP, (editors). Matrix Metalloproteinases. San Diego: Academic Press: 1998 p. 1-14.
2. 2. Birkedal-Hansen H, Moore WGI, Bodden MK, Windsor LJ, Birkedal-Hansen B, DeCarlo A, et al. Matrix Metalloproteinases: A review. Crit Rev Oral Biol Med 1993;4:197-250.
3. 3. Wilson CL, Matrisian LM. Matrilysin: An epithelial matrix metalloproteinase with potentially novel functions. Int J Biochem Cell Biol 1996;28:123-36.
4. 4. Crawford HC, Matrisian LM. Tumor and stromal expression of matrix metalloproteinases and their role in tumor progression. Invasion Metastasis 1994-95;14: 234-45.
5. 5. Shafie SM, Liotta LA. Formation of metastasis by human breast carcinoma cells (MCF-7) in nude mice. Cancer Letts 1980;11:81-7.
6. 6. Liotta LA, Thorgeirsson UP, Garbisa S. Role of collagenases in tumor cell invasion. Cancer Metastasis Rev 1982;1:277-88.
7. 7. Sato H, Seiki M. Membrane-type matrix metalloproleinases (MT-MMPs) in tumor metastasis. J Biochem 1996:119:209-15.
8. 8. Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997;89:1260-70.
9. 9. Newell KW Witty JP, Rodgers WH, Matrisian LM. Expression and localization of matrix-degrading metalloproteinases during colorectal tumorigenesis. Mol Carcinogenesis 1994;10:199-206.
10. 10. McDonnell S, Navre M, Coffey RJ, Matrisian LM. Expression and localization of the matrix metalloproteinase pump-1 (MMP-7) in human gastric and colon carcinomas. Mol Carcinogenesis 1991;4:527-33.
11. 11. Witty JP, McDonnell S, Newell KJ, Cannon P, Navre M, Tressler RJ, et al. Modulation of matrilysin levels in colon carcinoma cell lines affects tumorigenicity in vivo. Cancer Res 1994;54:4805-12.
12. 12. Muto T, Bussey HJR, Morson BC. The evolution of cancer of the colon and rectum. Cancer 1975;36:2251-70.
13. 13. Smith AJ, Stern HS, Penner M, Hay K, Mitri A, Bapat BV, et al. Somatic APC and K-ras codon 12 mutations in aberrant crypt foci from human colons. Cancer Res 1994;54:5527-30.
14. 14. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
15. 15. Groden J, Thilveris A, Samowitz W, Carlson M, Gelbert L, Albertsen H, et al. Identification and characterization of the familial adenomatous polyposis gene. Cell 1991;66:589-600.
16. 16. Powell SM, Zilz N, Beazer-Barclay Y, Bryan TM, Hamilton SR, Thibodeau SN, et al. APC mutations occur early during colorectal tumorigenesis. Nature 1992;359: 235-7.
17. 17. Miyaki M, Konishi M, Kukuchi-Yanoshita R, Enomoto M, Igari T, Tanaka K, et al. Characterization of somatic mutations of the adenomatous polyposis coli gene in colorectal tumors. Cancer Res 1994;54:3011-20.
18. 18. Moser AR, Pilot HC, Dove WF. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 1990;247:322-4.
19. 19. Su L, Kinzler KW, Vogelstein B, Preisinger AC, Moser AR, Luongo C, et al. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 1992;256:668-70.
20. 20. Deschner EE, Long FC, Hakissian M, Cupo SH. Differential susceptibility of inbred mouse strains forecast by acute colonic proliferative responses to methylazoxymethanol. J. Natl Cancer Inst 1984;72:195-8.
21. 21. Vivona AA, Shpitz B, Medline A, Bruce WR, Hay K, Ward MA, et al. K-ras mutations in aberrant crypt foci, adenomas and adenocarcinomas during azoxymethane-induced colon carcinogenesis. Carcinogenesis 1993;14:1777-81.
22. 22. Maltzman T, Whittington J, Driggers L, Stephens J, Ahnen D. AOM-induced mouse colon tumors do not express full-length APC protein. Carcinogenesis 1997;18:2435-9.
23. 23. Wilson CL, Heppner KJ, Labosky PA, Hogan BLM, Matrisian LM. Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc Natl Acad Sci USA 1997;94:1402-7.
24. 24. McLellan AE, Bird RP. Aberrant crypts: potential preneoplastic lesions in the murine colon. Cancer Res 1988;48:6187-92.
25. 25. Pretlow TP, Barrow BJ, Aston WS, O'Riordan MA, Pretlow TG, Jurcisek JA, et al. Abberant crypts: putative preneoplastic foci in human colonic mucosa. Cancer Res 199 1;51:1564-7.
26. 26. Rubinfeld B, Albert I, Porfiri E, Munemitsu S, Polakis P. Loss of β-catenin regulation by the APC tumor suppressor protein correlates with loss of structure due to common somatic mutations of the gene. Cancer Res 1997;57:4624-30.
27. 27. Polakis P. The adenomatous polyposis coli (APC) tumor suppressor. Biochim Biophys Acta 1997;1332: F127-47.
28. 28. Behrens J, Von Kries JP, Kuhl M, Bruhn D, Wedlich D, Grosschedl R, et al. Functional interaction of β-catenin with the transcription factor LEF-1. Nature 1996; 382:638-42.
29. 29. Huber O, Korn R, McLaughlin J, Ohsugi M, Herrman BG, Kemler R. Nuclear localization of β-catenin by interaction with the transcription factor LEF-1. Mech Dev 1996;59:3-10.
30. 30. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, et al. Activation of β-catenin-Tcf signaling in colon cancer by mutations in β-catenin or APC. Science 1997;275:1787-90.
31. 31. Peifer M. β-catenin as oncogene: the smoking gun. Science 1997;275:1752-3.
32. 32. Crawford HC, Fingleton BM, Rudolph-Owen LA, Heppner Goss KJ, Rubinfeld B, Polakis P, et al. The metalloproteinase matrilysin is a target of β-catenin transactivation in intestinal tumors. Oncogene (in press).
33. 33. Giese K, Cox J, Grosschedl R. The HMG domain of lymphoid enhancer factor 1 bends DNA and facilitates assembly of functional nucleoprotein structures. Cell 1992;69:185-95.
34. 34. Love JJ, Li X, Case DA, Giese K, Grosschedl R, Wright PE. Structural basis for the DNA bending by the architectural transcription factor LEF-1. Nature 1995; 376:791-5.
35. 35. Gearing AJH, Beckett P, Christodoulou M, Clements J, Davidson AH, et al. Processing of tumour necrosis factor-α precursor by metalloproteinases. Nature 1994; 370:555-7.
36. 36. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells. Nature 1997;385:729-32.
37. 37. Moss ML, Catherine Jin S-L, Milla ME, Burkhart W, Carter HL, Chen W-J, et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α. Nature 1997;385:733-6.
38. 38. Arribas J, Coodly L, Vollmer P, Kishimoto TK, Rose-John S, Massague J. Diverse cell surface protein ectodomains are shed by a system sensitive to metalloprotease inhibitors. J Biol Chem 1996;271:11376-82.
39. 39. Mulberg J, Durie FH, Otten-Evans C, Alderson MR, Rose-John S, Cosman D, et al. A metalloprotease inhibitor blocks shedding of the IL-6 receptor and the p60 TNF receptor. J Immunol 1995;155:5198-205.
40. 40. Dempsey PJ, Meise KS, Yoshitake Y, Nishikawa K, Coffey RJ. Apical enrichment of human EGF precursor in Madin-Darby canine kidney cells involves preferential basolateral ectodomain cleavage sensitive to a metalloprotease inhibitor. J Cell Biol 1997;138:747-58.
41. 41. Shirai H, Ueno E, Osaki M, Tatebe S, Ito H, Kaibara N. Expression of growth factors and their receptors in human early colorectal carcinomas: immunohistochemical study. Anticancer Res 1995;15:2889-94.
42. 42. Ciardiello F, Kim N, Saeki T, Dono R, Persico MG, Plowman GD, et al. Differential expression of epidermal growth factor-related proteins in human colorectal tumors. Proc Natl Acad Sci USA 1991;88:7792-6.
43. 43. Suzuki M, Raab G, Moses MA, Fernandez CA, Klagsbrun M. Matrix metalloproteinase-3 releases active heparin-binding EGF-like growth factor by cleavage at a specific juxtamembrane site. J Biol Chem 1997;272: 31730-7.
44. 44. Lahm H, Amsted P, Wyniger J, Yilmaz A, Fischer JR, Schreyer M, et al. Blockade of the insulin-like growth factor-I receptor inhibits growth of human colorectal cancer cells: evidence of a functional IGF-II mediated autocrine loop. Int J Cancer 1994;58:452-9.
45. 45. Collett-Solberg PF, Cohen R The role of the insulin-like growth factor binding proteins and the IGFBP proteases in modulating IGF action. Endocrin Met Clinics N Amer 1996;25:591-626.
46. 46. Fowlkes JL, Thrailkill KM, Serra DM, Suzuki K, Hagase H. Matrix metalloproteinases as insulin-like growth factor-binding protein-degrading proteinases. Prog Growth Fac Res 1995;6:255-63.
47. 47. Kayagaki N, Kawasaki A, Ebata T, Ohmoto H, Ikeda 5. Inoue S, et al. Metalloproteinases-mediated release of human Fas ligand. J Exp Med 1995;182:1777-83.
48. 48. Tanaka M, Itai T, Adachi M, Nagata S. Downregulation of Fas ligand by shedding. Nature Med 1998;4:31-6.
49. 49. Nagashima Y, Hasegawa S, Koshigawa N, Taki A, Ichikawa Y, Kitamura H, et al. Expression of matrilysin in vascular endothelial cells adjacent to matrilysin-producing tumors. Int J Cancer 1997;72:441-5.
50. 50. Heppner KJ, Brown PD, Matrisian LM. Differing effects of endogenous and synthetic inhibitors of metalloproteinases on intestinal tumorigenesis. Int J Cancer 1998;78:629-35.